GlassScriptPhysician profile
Amy L Randolph
NPI 1285019000
$2,161.91
in general payments reported to CMS, 2019-2025
31 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.94 · 2024: $619 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $242.07 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $211.71 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $150.03 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $126.39 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $125.76 | 2024-2025 | Fasenra, Breztri, Tezspire |
| Novo Nordisk INC | $113.16 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $110.81 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Genzyme Corporation | $108.31 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $96.55 | 2024-2025 | Lumryz |
| Pfizer INC. | $93.55 | 2024-2025 | |
| Pulmonx Corporation | $90.68 | 2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Bayer Healthcare Pharmaceuticals INC. | $85.64 | 2024-2025 | |
| Viatris Specialty LLC | $67.73 | 2025 | Yupelri |
| 3b Medical, INC. | $57.22 | 2025 | Luna |
| Mallinckrodt Hospital Products INC. | $55.87 | 2024 | Acthar |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.55 | 2024-2025 | Capvaxive, Winrevair |
| Amgen INC. | $46.50 | 2024-2025 | Repatha, Otezla, Repatha |
| Harmony Biosciences LLC | $42.50 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.49 | 2025 | Ofev |
| Csl Behring | $34.20 | 2025 | Hizentra |
| Baxter Healthcare | $29.33 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $28.15 | 2025 | Smartvest |
| Inspire Medical Systems, INC. | $25.68 | 2024 | Inspire |
| Grifols USA, LLC | $23.01 | 2025 | Prolastin-C Liquid |
| Abbvie INC. | $20.50 | 2024 | |
| Insmed, INC. | $18.32 | 2025 | Arikayce |
| Shield Therapeutics INC | $17.48 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.23 | 2025 | |
| Mylan Specialty L.P. | $14.64 | 2024 | Yupelri |
| Organon LLC | $12.94 | 2021 | |
| Phathom Pharmaceuticals, INC. | $9.91 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Randolph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.